Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical trial NCT04128696 · TERMINATED

Trial details

NCT number: NCT04128696
Sponsor: GlaxoSmithKline
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Neoplasms, Head and Neck

Start date: 2019-11-21
Primary completion: 2021-04-27
Enrollment: 315

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.